Anúncio
Anúncio
CADL
Candel Therapeutics, Inc. Common Stock
5.71
USDPatrocinado
+0.15
+2.70%
09 de jan., 15:59 UTC -5
Encerrado
Pré-Mercado
5.69
-0.02
-0.33%
Relatórios de Lucros CADL
Rácio de surpresa positiva
CADL separação 8 de 15 últimas estimativas.
53%
Próximo Relatório
Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.25
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+19.05%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/-37.50%
Candel Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 de nov. de 2025, CADL reported earnings of -0.21 USD per share (EPS) for Q3 25, missing the estimate of -0.18 USD, resulting in a -11.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an aumentar of 19.05% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Candel Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Candel Therapeutics, Inc. Common Stock reported EPS of -$0.21, missing estimates by -11.23%, and revenue of $0.00, 0% as expectations.
How did the market react to Candel Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -6.3%, changed from $4.92 before the earnings release to $4.61 the day after.
When is Candel Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 23 de mar. de 2026.
What are the forecasts for Candel Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analistas, Candel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio